Mepazine is a potent and selective MALT1 protease inhibitor used for inhibiting the viability of activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) cells by inducing apoptosis; it shows minimal effect on germinal center B-cell-like DLBCL (GCB-DLBCL) cells. It is applied in vitro and in vivo to suppress tumor growth and expansion of ABC-DLBCL cell lines (e.g., OCI-Ly10) in xenograft mouse models of DLBCL.